Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223
-
A. Rodriguez-Vida [1] ; M. D. Torregrosa [2] ; Á. Pinto [3] ; M. Á. Climent [4] ; D. Olmos [5] ; J. Carles [6]
-
[1] Hospital del Mar
Hospital del Mar
Barcelona, España
-
[2] Hospital Universitario Doctor Peset
Hospital Universitario Doctor Peset
Valencia, España
-
[3] Hospital Universitario La Paz
Hospital Universitario La Paz
Madrid, España
-
[4] Instituto Valenciano de Oncologia
Instituto Valenciano de Oncologia
Valencia, España
-
[5] Centro Nacional de Investigaciones Oncológicas
Centro Nacional de Investigaciones Oncológicas
Madrid, España
-
[6] Hospital Universitario Vall d’Hebron, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 6 (June 2018), 2018, págs. 679-686
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Despite the improvement provided by androgenic suppression in the treatment of prostate cancer, most of tumors develop resistance to castration. However, new therapies have demonstrated an increase in patient survival such as radium-223 (Ra-223), an alpha emitter and calcium mimetic with the capability of targeting osteoblastic metastatic lesions. According to results of the ALSYMPCA phase III trial, Ra-223 has demonstrated its activity by improving symptoms and survival of patients with metastatic castration-resistant prostate cancer (mCRPC), symptomatic bone metastases, and no known visceral metastatic disease, without interfering with subsequent treatments. This review examines the key evidence to establish the best patient selection criteria to use Ra-223, how to assess the response to treatment, treatment-related toxicity, and follow-up, but also current research regarding imaging techniques and biomarkers to assess the efficacy of Ra-223. Finally, we briefly describe the clinical trials that are currently ongoing with Ra-223.
